Comparison of cardiac resynchronization therapy outcomes in patients with New York Heart Association functional class I/II versus III/IV heart failure

Alan J. Bank, Ariel Rischall, Ryan M. Gage, Kevin V. Burns, Spencer H. Kubo

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: Several randomized trials have shown that cardiac resynchronization therapy (CRT) benefits New York Heart Association (NYHA) functional class I/II heart failure (HF) patients, but it is unknown if similar outcomes occur in the real-world. Methods and Results: All patients receiving CRT between 2003 and 2008 with ejection fraction (EF) ≤35% and QRS duration ≥120 ms were included. Outcomes assessed were subjective clinical response, echocardiographic response, and survival free of cardiovascular (CV) hospitalization. Baseline demographics in functional class I/II (n = 155) and functional class III/IV (n = 512) were similar, except for differences in age and several comorbidities. Clinical response was similar in both groups. The functional class I/II group had a greater decrease in left ventricular (LV) end-diastolic dimension (P =.031), and trended toward greater improvements in LV end-systolic dimension (P =.056) and EF (P =.059). The functional class I/II group had a better 5-year survival rate (79 vs 54%; P <.0001) and survival free of CV hospitalization (45% vs 26%; P <.0001). Conclusions: In this real-world clinical scenario, NYHA functional class I/II CRT patients improved clinical status, and LV function and size as good as or better than those in NYHA functional class III/IV patients. These observations provide further support for the use of CRT in patients with mild symptoms of HF.

Original languageEnglish (US)
Pages (from-to)373-378
Number of pages6
JournalJournal of Cardiac Failure
Volume18
Issue number5
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Cardiac Resynchronization Therapy
Heart Failure
Hospitalization
Survival
Left Ventricular Function
Comorbidity
Survival Rate
Demography

Keywords

  • Cardiac resynchronization therapy
  • heart failure
  • NYHA functional classification
  • remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of cardiac resynchronization therapy outcomes in patients with New York Heart Association functional class I/II versus III/IV heart failure. / Bank, Alan J.; Rischall, Ariel; Gage, Ryan M.; Burns, Kevin V.; Kubo, Spencer H.

In: Journal of Cardiac Failure, Vol. 18, No. 5, 01.01.2012, p. 373-378.

Research output: Contribution to journalReview article

@article{e1ba93efef0f4c17b41644ad35978c07,
title = "Comparison of cardiac resynchronization therapy outcomes in patients with New York Heart Association functional class I/II versus III/IV heart failure",
abstract = "Background: Several randomized trials have shown that cardiac resynchronization therapy (CRT) benefits New York Heart Association (NYHA) functional class I/II heart failure (HF) patients, but it is unknown if similar outcomes occur in the real-world. Methods and Results: All patients receiving CRT between 2003 and 2008 with ejection fraction (EF) ≤35{\%} and QRS duration ≥120 ms were included. Outcomes assessed were subjective clinical response, echocardiographic response, and survival free of cardiovascular (CV) hospitalization. Baseline demographics in functional class I/II (n = 155) and functional class III/IV (n = 512) were similar, except for differences in age and several comorbidities. Clinical response was similar in both groups. The functional class I/II group had a greater decrease in left ventricular (LV) end-diastolic dimension (P =.031), and trended toward greater improvements in LV end-systolic dimension (P =.056) and EF (P =.059). The functional class I/II group had a better 5-year survival rate (79 vs 54{\%}; P <.0001) and survival free of CV hospitalization (45{\%} vs 26{\%}; P <.0001). Conclusions: In this real-world clinical scenario, NYHA functional class I/II CRT patients improved clinical status, and LV function and size as good as or better than those in NYHA functional class III/IV patients. These observations provide further support for the use of CRT in patients with mild symptoms of HF.",
keywords = "Cardiac resynchronization therapy, heart failure, NYHA functional classification, remodeling",
author = "Bank, {Alan J.} and Ariel Rischall and Gage, {Ryan M.} and Burns, {Kevin V.} and Kubo, {Spencer H.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.cardfail.2012.01.015",
language = "English (US)",
volume = "18",
pages = "373--378",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Comparison of cardiac resynchronization therapy outcomes in patients with New York Heart Association functional class I/II versus III/IV heart failure

AU - Bank, Alan J.

AU - Rischall, Ariel

AU - Gage, Ryan M.

AU - Burns, Kevin V.

AU - Kubo, Spencer H.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: Several randomized trials have shown that cardiac resynchronization therapy (CRT) benefits New York Heart Association (NYHA) functional class I/II heart failure (HF) patients, but it is unknown if similar outcomes occur in the real-world. Methods and Results: All patients receiving CRT between 2003 and 2008 with ejection fraction (EF) ≤35% and QRS duration ≥120 ms were included. Outcomes assessed were subjective clinical response, echocardiographic response, and survival free of cardiovascular (CV) hospitalization. Baseline demographics in functional class I/II (n = 155) and functional class III/IV (n = 512) were similar, except for differences in age and several comorbidities. Clinical response was similar in both groups. The functional class I/II group had a greater decrease in left ventricular (LV) end-diastolic dimension (P =.031), and trended toward greater improvements in LV end-systolic dimension (P =.056) and EF (P =.059). The functional class I/II group had a better 5-year survival rate (79 vs 54%; P <.0001) and survival free of CV hospitalization (45% vs 26%; P <.0001). Conclusions: In this real-world clinical scenario, NYHA functional class I/II CRT patients improved clinical status, and LV function and size as good as or better than those in NYHA functional class III/IV patients. These observations provide further support for the use of CRT in patients with mild symptoms of HF.

AB - Background: Several randomized trials have shown that cardiac resynchronization therapy (CRT) benefits New York Heart Association (NYHA) functional class I/II heart failure (HF) patients, but it is unknown if similar outcomes occur in the real-world. Methods and Results: All patients receiving CRT between 2003 and 2008 with ejection fraction (EF) ≤35% and QRS duration ≥120 ms were included. Outcomes assessed were subjective clinical response, echocardiographic response, and survival free of cardiovascular (CV) hospitalization. Baseline demographics in functional class I/II (n = 155) and functional class III/IV (n = 512) were similar, except for differences in age and several comorbidities. Clinical response was similar in both groups. The functional class I/II group had a greater decrease in left ventricular (LV) end-diastolic dimension (P =.031), and trended toward greater improvements in LV end-systolic dimension (P =.056) and EF (P =.059). The functional class I/II group had a better 5-year survival rate (79 vs 54%; P <.0001) and survival free of CV hospitalization (45% vs 26%; P <.0001). Conclusions: In this real-world clinical scenario, NYHA functional class I/II CRT patients improved clinical status, and LV function and size as good as or better than those in NYHA functional class III/IV patients. These observations provide further support for the use of CRT in patients with mild symptoms of HF.

KW - Cardiac resynchronization therapy

KW - heart failure

KW - NYHA functional classification

KW - remodeling

UR - http://www.scopus.com/inward/record.url?scp=84860440411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860440411&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2012.01.015

DO - 10.1016/j.cardfail.2012.01.015

M3 - Review article

C2 - 22555266

AN - SCOPUS:84860440411

VL - 18

SP - 373

EP - 378

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 5

ER -